Bristol-Myers Squibb Company (NYSE:BMY) – Analysts at SunTrust Banks decreased their FY2017 earnings per share estimates for Bristol-Myers Squibb in a research report issued on Thursday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will post earnings of $2.95 per share for the year, down from their previous forecast of $2.96. SunTrust Banks also issued estimates for Bristol-Myers Squibb’s FY2018 earnings at $3.15 EPS and FY2019 earnings at $3.58 EPS.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the company posted $0.69 earnings per share. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year.
COPYRIGHT VIOLATION NOTICE: This story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/19/analysts-issue-forecasts-for-bristol-myers-squibb-companys-fy2017-earnings-bmy.html.
Several other research firms also recently issued reports on BMY. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target on the stock. in a research report on Thursday, September 7th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 8th. Jefferies Group LLC increased their price target on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target on the stock. in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $62.66.
Shares of Bristol-Myers Squibb (BMY) opened at 62.70 on Monday. The company has a 50 day moving average price of $58.77 and a 200 day moving average price of $55.98. The company has a market cap of $102.82 billion, a price-to-earnings ratio of 22.90 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $63.47.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
In other news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
A number of institutional investors have recently bought and sold shares of BMY. DnB Asset Management AS increased its holdings in Bristol-Myers Squibb by 60.9% in the 1st quarter. DnB Asset Management AS now owns 474,006 shares of the biopharmaceutical company’s stock valued at $25,776,000 after purchasing an additional 179,500 shares during the last quarter. Patten & Patten Inc. TN grew its stake in shares of Bristol-Myers Squibb by 2.1% in the first quarter. Patten & Patten Inc. TN now owns 132,428 shares of the biopharmaceutical company’s stock worth $7,201,000 after acquiring an additional 2,717 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 1.8% in the first quarter. Nisa Investment Advisors LLC now owns 610,253 shares of the biopharmaceutical company’s stock worth $33,186,000 after acquiring an additional 10,541 shares in the last quarter. Quantitative Systematic Strategies LLC grew its stake in shares of Bristol-Myers Squibb by 447.5% in the first quarter. Quantitative Systematic Strategies LLC now owns 32,128 shares of the biopharmaceutical company’s stock worth $1,747,000 after acquiring an additional 26,260 shares in the last quarter. Finally, Hartford Financial Management Inc. grew its stake in shares of Bristol-Myers Squibb by 1.8% in the first quarter. Hartford Financial Management Inc. now owns 69,247 shares of the biopharmaceutical company’s stock worth $3,765,000 after acquiring an additional 1,223 shares in the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.